Pacific Biosciences of California Inc (NAS:PACB)
$ 1.86 -0.07 (-3.63%) Market Cap: 568.03 Mil Enterprise Value: 1.02 Bil PE Ratio: 0 PB Ratio: 1.17 GF Score: 55/100

Pacific Biosciences of California Inc at Morgan Stanley Global Healthcare Conference Transcript

Sep 14, 2022 / 05:30PM GMT
Release Date Price: $6.13 (-0.16%)
Tejas Rajeev Savant
Morgan Stanley, Research Division - Equity Analyst

Hey, everyone. Good afternoon. My name is Tejas Savant, and I'm the life science, tools and diagnostics analyst at Morgan Stanley. It's my pleasure this afternoon to host PacBio. And from the company, we have Christian Henry; and Susan Kim, CEO and CFO respectively. Thanks guys for doing this.

Before we get started, I need to rattle off the disclosures. Please see the Morgan Stanley research disclosure website at morganstanley.com/researchdisclosures. And if you have any questions, do reach out to your sales rep.

Questions & Answers

Tejas Rajeev Savant;Christian O. Henry
Morgan Stanley, Research Division - Equity Analyst;Pacific Biosciences of California, Inc.

So Christian, maybe just to set the stage and kick things off for us, can you just walk us through 2022? Because I feel like, in a sense, the numbers didn't do justice to a lot of the stuff you had going on inside the company? And what are you most excited about as you look to 2023?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot